Jeffrey Klomp, PhD
Targeting Hypoxia-Driven Drug Vulnerabilities in Pancreatic Cancer Through Repurposing of Clinically Actionable Compounds
Pancreatic tumors often grow with very little oxygen, which forces cancer cells onto different survival pathways and changes how they respond to cancer-driving signals such as KRAS and ERK. The lab will screen a library of existing, clinically relevant medicines for compounds that work especially well against cancer cells in low oxygen or that boost KRAS-targeted therapies. Because many of these drugs are already approved or have well-established safety profiles, promising discoveries could move toward patients faster.
Dr. Jeffrey Klomp is an Assistant Professor in the Department of Medicine at Michigan State University's College of Human Medicine, with his lab in the MSU biomedical research complex in Grand Rapids. He studies the systems biology of cancer adaptations, focusing on the oncogene KRAS and the signaling enzyme ERK. A Michigan native, he trained at the Van Andel Research Institute, the University of Chicago and the University of Illinois, and most recently at the University of North Carolina under Dr. Channing Der, a pioneer in the discovery of the human RAS gene. He collaborates with members of the HFH+MSU Pancreatic Cancer Center.
Seed grants start at $50,000 — awarded by scientists, reported on annually.
Donate →Jeffrey Klomp, PhD
Targeting Hypoxia-Driven Drug Vulnerabilities in Pancreatic Cancer Through Repurposing of Clinically Actionable Compounds
Pancreatic tumors often grow with very little oxygen, which forces cancer cells onto different survival pathways and changes how they respond to cancer-driving signals such as KRAS and ERK. The lab will screen a library of existing, clinically relevant medicines for compounds that work especially well against cancer cells in low oxygen or that boost KRAS-targeted therapies. Because many of these drugs are already approved or have well-established safety profiles, promising discoveries could move toward patients faster.
Dr. Jeffrey Klomp is an Assistant Professor in the Department of Medicine at Michigan State University's College of Human Medicine, with his lab in the MSU biomedical research complex in Grand Rapids. He studies the systems biology of cancer adaptations, focusing on the oncogene KRAS and the signaling enzyme ERK. A Michigan native, he trained at the Van Andel Research Institute, the University of Chicago and the University of Illinois, and most recently at the University of North Carolina under Dr. Channing Der, a pioneer in the discovery of the human RAS gene. He collaborates with members of the HFH+MSU Pancreatic Cancer Center.
Seed grants start at $50,000 — awarded by scientists, reported on annually.
Donate →